

RESEARCH PAPER

Cross-talk between toll-like receptor 4 (TLR4) and proteinase-activated receptor 2 (PAR₂) is involved in vascular function

M Bucci^{1*}, V Vellecco^{1*}, L Harrington², V Brancaleone^{1,5}, F Roviezzo¹, G Mattace Raso¹, A Ianaro¹, G Lungarella³, R De Palma⁴, R Meli¹ and G Cirino¹

¹Department of Experimental Pharmacology, Faculty of Pharmacy, University of Naples 'Federico II', Napoli, Italy, ²Cardiothoracic Pharmacology, Imperial College, London, UK, ³Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy, ⁴Dipartimento di Internistica Clinica e Sperimentale, Seconda Università di Napoli, Napoli, Italy, and ⁵Dipartimento di Scienze, Università degli Studi della Basilicata, Potenza, Italy

Correspondence

Professor Giuseppe Cirino,
Department of Experimental
Pharmacology, Faculty of
Pharmacy, University of Naples
'Federico II' via Domenico
Montesano 49, 80131 Naples,
Italy. E-mail: cirino@unina.it

*These authors equally
contributed to this paper.

Keywords

PAR₂; TLR4; vasodilatation;
hypotension

Received

6 December 2011

Revised

16 July 2012

Accepted

6 August 2012

BACKGROUND AND PURPOSE

Proteinase-activated receptors (PARs) and toll-like receptors (TLRs) are involved in innate immune responses. The aim of this study was to evaluate the possible cross-talk between PAR₂ and TLR4 in vessels in physiological condition and how it varies following stimulation of TLR4 by using *in vivo* and *ex vivo* models.

EXPERIMENTAL APPROACH

Thoracic aortas were harvested from both naïve and endotoxaemic rats for *in vitro* studies. Arterial blood pressure was monitored in anaesthetized rats *in vivo*. LPS was used as a TLR4 agonist while PAR₂ activating peptide (AP) was used as a PAR₂ agonist. Aortas harvested from TLR4^{-/-} mice were also used to characterize the PAR₂ response.

KEY RESULTS

PAR₂, but not TLR4, expression was enhanced in aortas of endotoxaemic rats. PAR₂AP-induced vasorelaxation was increased in aortic rings of LPS-treated rats. TLR4 inhibitors, curcumin and resveratrol, reduced PAR₂AP-induced vasorelaxation and PAR₂AP-induced hypotension in both naïve and endotoxaemic rats. Finally, in aortic rings from TLR4^{-/-} mice, the expression of PAR₂ was reduced and the PAR₂AP-induced vasodilatation impaired compared with those from wild-type mice and both resveratrol and curcumin were ineffective.

CONCLUSIONS AND IMPLICATIONS

Cross-talk between PAR₂ and TLR4 contributes to vascular homeostasis.

Abbreviations

Chl, chlorisondamine; CRC, curcumin; MABP, mean arterial blood pressure; PAR₂AP, protease activated receptor-2 activating peptide; PE, phenylephrine; RSV, resveratrol; TLR4, toll like receptor-4

Introduction

Proteinase-activated receptor 2 (PAR₂) is a member of the seven-transmembrane GPCR superfamily activated by proteo-

lytic cleavage (Macfarlane *et al.*, 2001; Hollenberg and Compton, 2002). All PARs share a unique mechanism of activation where the serine proteases cleave at specific sites within the extracellular N-terminus to unmask a tethered

ligand domain that interacts with the receptor in the extracellular loop II initiating signalling. This process is irreversible because once cleaved, PARs can no longer be used by the cell, so they are degraded and signalling is terminated (Cottrell *et al.*, 2003). Thus far, four PAR receptors have been described: PAR₁, PAR₂, PAR₃ and PAR₄ (Hollenberg, 1999). While the ligand for PAR₁, PAR₃ and PAR₄ has been identified as thrombin, PAR₂ can be activated by trypsin (Nystedt *et al.*, 1994), tryptase (Molino *et al.*, 1997) and factor Xa (Fox *et al.*, 1997), but not thrombin (Cicala, 2002). PAR₂ can be activated by a specific synthetic peptide [PAR₂ activating peptide (AP)], which, by mimicking the specific tethered ligand sequence SLIGRL, can activate the receptor without causing proteolysis (Dery *et al.*, 1998). In the last decade, we and others have demonstrated that PAR₂ is expressed in vascular tissues and exposure to LPS results in it being up-regulated both *in vitro* and *in vivo*, suggesting a possible role for PAR₂ in endotoxaemia (Nystedt *et al.*, 1996; Cicala *et al.*, 1999; Morello *et al.*, 2005). The notion that PAR₂ is overexpressed in inflammatory-based diseases is supported by the literature; however, it has not been well established whether this receptor has a protective or detrimental role (Bucci *et al.*, 2005).

Recently, a new emerging family of receptors has been identified as a front line subsystem against invasive microorganisms for both innate and adaptive immunity namely toll-like receptors (TLR) (Iwasaki and Medzhitov, 2004). To date, 12 TLRs have been identified in both vertebrates and invertebrates (Hoffmann and Reichhart, 2002; Roach *et al.*, 2005), and all of them are involved in triggering defensive antimicrobial immune responses (Akira and Hemmi, 2003; Akira *et al.*, 2006; Zhang and Schluesener, 2006). TLRs recognize specific motifs found in microorganisms, but not in eukaryotes, designed as pathogen-associated molecular patterns (PAMPs) (Aderem and Ulevitch, 2000; Janeway and Medzhitov, 2002). Once activated by PAMPs, TLRs initiate a signal transduction cascade that leads to NF- κ B activation with the production of pro-inflammatory cytokines, such as TNF- α , IL-1 and IL-6 (Barton and Medzhitov, 2004; Mitchell *et al.*, 2007). In particular, TLR4 signal transduction has been recognized as a key pathway for the lipid A moiety of LPS, from gram-negative bacteria, to induce activation of various cells stimulating widespread inflammation and activating coagulation cascades (Lolis and Bucala, 2003; O'Neill and Bowie, 2007; Nakamura *et al.*, 2008).

Recent studies have demonstrated that PARs, together with TLRs and nucleotide-binding oligomerization domain (NOD) receptors, are a part of the innate immune response. Indeed, a complex interplay between the different receptors of these three families is required for appropriate innate immune responses to different types of bacteria; this bacterial-host communication leads to the activation of several signal transduction pathways with consequent production of cytokines, antimicrobial peptides and apoptosis (Chung *et al.*, 2010). In this context, it has been demonstrated that PAR₂ activation participates in the pathogenesis of periodontitis caused by *Porphyromonas gingivalis* (Holzhausen *et al.*, 2006), colitis caused by *Citrobacter rodentium* (Hansen *et al.*, 2005), and in infections sustained by *Serratia marcescens* (Kida *et al.*, 2007) and *Pseudomonas aeruginosa* (Kida *et al.*, 2008). Moreover, it has been shown that in transiently PAR₂-transfected HEK293T cells, a synergistic

action between PAR₂ and TLR4 takes place, suggesting cooperation between these two receptors in NF- κ B-mediated inflammatory responses (Rallabhandi *et al.*, 2008). These findings clearly suggest interplay between PAR₂ and TLR4 in infection-based inflammatory diseases, where PAR₂ and TLR4 activation is enhanced, and their cooperation is valuable. However, the cross-talk between PAR₂ and TLR4 in normal physiological environments has been less well investigated. Hence, the aim of this study was to use *in vivo* and *ex vivo* models to evaluate any possible cross-talk between PAR₂ and TLR4 in vascular tissues in physiological conditions and how it varies following stimulation of TLR4.

Methods

Animals

All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010). Male C57BL/10ScN mice and male Wistar rats (total number of rats used = 50) were purchased from Harlan, Udine, Italy. Male C57BL/10Cr (TLR4^{-/-}) mice were a generous gift from Prof. S. Cuzzocrea, University of Messina, Italy. All mice used for the experiments (total number used = 60) were 6–8 weeks of age. Animals were kept at a temperature of 23 \pm 2°C, humidity range of 40 to 70% and 12h light/dark cycles. Food and water were available *ad libitum*.

TLR4^{-/-} mice were homozygous for a 74-kb genomic deletion encompassing *Thr4* that resulted in the absence of both its mRNA and protein and made them refractory to the biological activity of LPS (Poltorak *et al.*, 1998; 2000). All animal procedures were performed according to the Declaration of Helsinki of the European Community guidelines for the use of experimental animals and authorized by Centro Servizi Veterinari Università degli Studi di Napoli 'Federico II'.

Reagents

PAR₂AP (SLIGKV-NH₂) was synthesized by standard solid-phase 9-fluorenylmethoxycarbonyl chemistry with an automated peptide synthesizer (model 432A, Applied Biosystems, Carlsbad, CA, USA). Peptide was purified by reverse-phase HPLC, and its identity was confirmed by MS, as described previously. Urethane, heparin, resveratrol (RSV), curcumin (CRC), ACh, phenylephrine (PE), DMSO, SOD and LPS from *Escherichia coli* 0.127:B8 were purchased from Sigma Chemical Co. (Milan, Italy). Chlorisondamine (Chl) was purchased from Tocris Cookson (Avon, England).

Blood pressure measurement

Male Wistar rats (Harlan) weighing 250–300 g were anaesthetized with urethane (solution 15% w/vol⁻¹; 1.5 g·kg⁻¹ i.p.). depth anaesthesia was assessed by checking both abdominal and pedal withdrawal reflex throughout the duration of the experiment. Once anaesthetized, rats were pretreated with the irreversible ganglion-blocking agent, Chl (2.5 mg·kg⁻¹ i.p.) in order to eliminate any influence of autonomic nervous system activation on changes in mean arterial blood pressure (MABP) induced by PAR₂AP (Cicala *et al.*, 2001). The right jugular vein and the left carotid artery were cannulated

for drug administration and blood pressure measurement, respectively. The left carotid artery was connected to a pressure transducer (Ugo Basile, Comerio, Italy) and changes in arterial blood pressure were recorded continuously with a computerized system (Biopac System TCI 102; Ugo Basile). CRC (100 mg·kg⁻¹) or RSV (30 mg·kg⁻¹) were administered by oral gavage 1 h before an i.v. injection of PAR₂AP. After surgery, arterial blood pressure was allowed to stabilize for about 30 min. Once the blood pressure was stable, PAR₂AP (0.3 mg·kg⁻¹) or vehicle (saline) was administered i.v. every 20 min for three consecutive times, and blood pressure was monitored for a total time of 60 min. The change in MABP, as previously described, (Cicala *et al.*, 1999) was characterized by a rapid fall lasting 1 min. There was no tolerance to the hypotensive effect of PAR₂AP (data not shown). Groups of six rats for each treatment were used. Blood pressure values were expressed as MABP calculated as area under the curve obtained following PAR₂AP administration. The MABP values were monitored every 10 s up to 1 min.

Ex vivo studies

Male Wistar rats (Harlan) weighing 250–300 g ($n = 4$ for each group of treatment) were anaesthetized with enflurane, then LPS (13.5 × 10⁶ U·kg⁻¹) or an equal volume of saline, was injected i.v. through the caudal vein. The dose of LPS was chosen from a previous study (Cicala *et al.*, 1999). Four and 8 h after LPS or saline administration, the animals were killed and thoracic aortas was rapidly harvested, dissected and cleaned of adherent connective and fat tissue. Rings of 2–3-mm length were cut and placed in organ baths (2.5 mL) filled with oxygenated (95% O₂–5% CO₂) Krebs solution maintained at 37°C. The rings were connected to an isometric transducer (type 7006, Ugo Basile) and changes in tension were recorded continuously with a computerized system (Data Capsule 17400, Ugo Basile). The composition of the Krebs solution was as follow (mM): NaCl 118, KCl 4.7, MgCl₂ 1.2, KH₂PO₄ 1.2, CaCl₂ 2.5, NaHCO₃ 25, and glucose 10.1. The rings were initially stretched until a resting tension of 0.5 g was reached and allowed to equilibrate for at least 30 min, during which tension was adjusted, when necessary, to 0.5 g and bathing solution was periodically changed. In each experiment, rings were first challenged with PE (1 µM) until the responses were reproducible. To verify endothelium integrity, a cumulative concentration–response curve to ACh (10 nM–30 µM) was performed on PE-precontracted rings. The rings were then washed and contracted with PE (1 µM) and, once a plateau was reached, a cumulative concentration–response curve to PAR₂AP (10 nM–30 µM) was performed. A preliminary study on the optimal incubation time and concentration of the drug treatments was carried out (data not shown). CRC (10 µM; 15 min), RSV (10 µM; 15 min), SOD (300 U·mL⁻¹; 15 min) or vehicle (DMSO) were added in the organ baths; then the rings were contracted with PE (1 µM) and a cumulative concentration–response curve to PAR₂AP was performed.

In another set of experiments, a cumulative concentration–response curve to PAR₂AP, in the presence of CRC (10 µM; 15 min), RSV (10 µM 15 min) or vehicle (DMSO) was carried out on aortic rings harvested from both TLR4^{-/-} and C57BL/10ScN mice. Data are expressed as %

vasodilatation induced by the stimulus, when applied after a stable contraction had been obtained to 1 µM PE.

Quantification by real-time quantitative reverse transcriptase PCR (RT-PCR)

The presence of PAR₂ mRNA was determined by quantitative PCR. Briefly, total RNA from tissues of naïve and LPS-treated rats, and naïve and LPS TLR4^{-/-} and respective wild-type strain C57BL/10ScN was extracted by using TRIzol reagent (Invitrogen, Milan, Italy). Subsequently, to eliminate genomic DNA contamination, 1 µg of the above RNA was treated with RQ1 RNase-free DNase I (Promega Corporation, Madison, WI, USA) and reverse transcription was performed using M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's recommendations. Real-time RT-PCR was carried out with cDNAs by using Sybr Green PCR Master Mix (Applied Biosystems, Monza, Italy) and 7500 Real Time PCR System (Applied Biosystems, Foster City, CA, USA). All cDNA samples were run in triplicate in 25 µL reactions. Primers used were specifically designed using Primer Express Software 2.0 (Applied Biosystems) and validated for their specificity: FW:5'-CCGGGACGCAACAACAGTA-3' RV:5'-TTCCCAGTGA TTGGAGGCTG-3 product length = 71. GAPDH was used as internal control.

Samples were incubated at 50°C for 2 min and at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Differences in cDNA input were corrected by normalizing signals obtained with primers specific for GAPDH. To exclude non-specific amplification and/or the formation of primer dimers, control reactions were performed in the absence of target cDNA. Gene expression levels were calculated using the 2^{-ΔCT} method (Livak and Schmittgen, 2001) and are presented as ratio between mean fold change of target gene and GAPDH ± SEM.

Western blotting

Aortic tissue of naïve and LPS-treated rats, TLR4^{-/-} and respective wild-type strain C57BL/10ScN were homogenized in modified RIPA buffer (Tris HCl 50 mM, pH 7.4, tritonX-100 1%, sodium deoxycholate 0.25%, NaCl 150 mM, EDTA 1 mM, PMSF 1 mM, aprotinin 10 µg·mL⁻¹, leupeptin 20 mM, NaF 50 mM) using a polytron homogenizer (two cycles of 10 s at maximum speed). After centrifugation of homogenates at 9193×g for 15 min, protein concentration was determined by the Bradford assay using BSA as standard (Bio-Rad Laboratories, Milan, Italy); 30 µg of the denatured proteins or 40 µg of supernatants obtained from immunoprecipitates were separated on 10% or 8% SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked in PBS-Tween 20 (0.1%, v v⁻¹) containing 5% non-fat dry milk for 1 h at room temperature, and then incubated with anti-PAR₂ (1:500) or anti-TLR4 (1:1000) overnight at 4°C. The filters were washed with PBS-Tween 20 extensively for 30 min, before incubation, for 2 h at 4°C, with the secondary antibody (1:5000) conjugated with HRP antimouse IgG or antirabbit IgG, respectively. The membranes were then washed and immunoreactive bands were visualized using an Enhanced Chemiluminescence Substrate (Amersham Pharmacia Biotech, San Diego, CA, USA).

TLR4 immunoprecipitation and PAR₂ immunoblotting

All steps were performed at 4°C. Aortas, prepared from LPS-treated or saline-treated rats were washed with Krebs solution and homogenized in modified RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.25% sodium deoxycholate, 1 mM PMSF; 10 µg·mL⁻¹ aprotinin, 20 mM leupeptin, 50 mM NaF). After 30 min, homogenates were centrifuged for 10 min at 10789× *g* in an eppendorf microfuge in order to remove nuclei and cell debris, and 300 µL of the resulting supernatant (containing 400 µg of cleared lysate) were incubated overnight with the rabbit polyclonal anti-TLR4 antibody [TLR4 (M300) sc-30002, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA] or normal rabbit serum (to evaluate non-specific binding) on a rotating wheel. The antigen–antibody complexes were incubated for 2 h on a rotating wheel with protein A/G – plus Agarose (sc-2003, Santa Cruz Biotechnology, Inc.). After centrifugation at 23× *g* for 15 s, the supernatants were collected, transferred into eppendorfs and conserved at –80°C for Western blot analysis. The bound complexes were washed once with lysis buffer, twice with buffer A (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.2% Nonidet P40), twice with buffer B (10 mM Tris-HCl pH 7.4, 500 mM NaCl, 2 mM EDTA, 0.2% Nonidet P40), and once with 10 mM Tris-HCl pH 7.4. The supernatants of the beads were collected and immunoprecipitated material was eluted from the beads by boiling in Laemmli sample buffer and subjected to SDS-PAGE (8%). The blot was performed by transferring proteins from a gel to PVDF membrane at 250 mA for 40 min at room temperature. The filter was then blocked with 1× PBS, 5% non-fat dried milk for 1 h at room temperature and probed with monoclonal antibody anti-PAR₂ [1:500, PAR₂ (SAM11) sc-13504, Santa Cruz, Inc.] dissolved in 1× PBS, 5% non-fat dried milk at 4°C, overnight. The secondary antibody (anti-mouse IgG HRP conjugate 1:5000 dilution) was incubated for 2 h at 4°C. Subsequently, the blot was extensively washed with PBS, developed using enhanced chemiluminescence detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ, USA) according to the manufacturer's instructions, and exposed to Kodak X-Omat film (Eastman Kodak Co., Rochester, NY, USA). A protein band of about 40 kDa on X-ray film was obtained.

Statistical analysis

Data are expressed as mean ± SEM. Statistical analysis was determined by using one or two way ANOVA followed by Dunnett's or Bonferroni's test for multiple comparisons, respectively, using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). Differences were considered statistically significant when *P* was less than 0.05.

Results

PAR₂AP-induced vasorelaxation is increased in aortic rings from LPS-treated rats

As already previously shown (Cicala *et al.*, 1999), Western blot analysis revealed an enhanced expression of the PAR₂

receptor following LPS injection when compared with vehicle at all times tested (Supporting Information Figure S1A). PAR₂AP-induced vasorelaxation was increased in a time-dependent manner in rat aortic rings harvested 4 and 8 h following LPS administration (Supporting Information Figure S1B). Conversely, TLR4 expression was not modified after LPS treatments, at all times tested (Supporting Information Figure S1C).

TLR4 inhibitors, CRC and RSV, reduced PAR₂AP-induced relaxation in naïve and LPS-treated rats

In order to investigate any cross-talk between PAR₂ and TLR4 signalling, aortic rings were treated with two different compounds recently identified as inhibitors of the TLR4 pathway, CRC and RSV. CRC inhibits both ligand-induced (MyD88-dependent pathway) and ligand-independent (MyD88-independent, TIR-domain-containing adapter-inducing interferon-β (TRIF)-dependent pathway) dimerization of TLR4 (Youn *et al.*, 2006; Son *et al.*, 2008; Lubbad *et al.*, 2009), while RSV inhibits specifically the MyD88-independent, TRIF-dependent pathway (Youn *et al.*, 2005; Son *et al.*, 2008; Lubbad *et al.*, 2009). In order to verify the specificity of CRC and RSV, the maximal concentrations of either CRC (30 µM) or RSV (10 µM) were tested on ACh-induced vasodilatation. As shown in Figure 1, neither compound affected ACh-induced vasodilatation.

Both CRC (3, 10, 30 µM) and RSV (1, 3, 10 µM) significantly and in a concentration-dependent manner reduced PAR₂AP-induced vasorelaxation in naïve rats (Figures 2A, 3A). Similarly, in LPS-treated rats, both CRC (Figure 2B and C) and RSV (Figure 3B and C) also significantly inhibited PAR₂AP-induced vasorelaxation at the different time points tested. The inhibitory effects of CRC and RSV on PAR₂AP-induced vasorelaxation were not significantly different between aortic rings from naïve and endotoxaemic rats. Moreover, to exclude the possibility that the effect of CRC and RSV on PAR₂AP-induced vasorelaxation was caused by their antioxidant properties, we pre-treated aortic rings with SOD (300 U·mL⁻¹) at a concentration known to act as superoxide anion scavenger. SOD did not modify the PAR₂AP-induced vasorelaxation (EC₅₀ = 3.98 × 10⁻⁶ M and 3.80 × 10⁻⁶ M in the presence of vehicle and SOD, respectively, data not shown). Finally, to further confirm the specificity of CRC and RSV on TLR4 signalling, both inhibitors were tested on aortic rings harvested from TLR4^{-/-} mice. As shown in Figure 4C, both inhibitors failed to inhibit PAR₂AP-induced vasodilatation, while they still significantly inhibited the vasodilatation in vessels obtained from C57BL/10ScN mice (Supporting Information Figure S3C).

CRC and RSV reduced PAR₂AP-induced hypotension

In order to prove that hypotension induced by selective activation of the PAR₂ receptor involves TLR4 signalling, CRC (100 mg·kg⁻¹) and RSV (30 mg·kg⁻¹) were administered before i.v. administration of PAR₂AP. Both CRC and RSV inhibited PAR₂AP-induced hypotension *in vivo* in naïve rats (Figure 5).




Figure 1

Pre-incubation of aortic rings with CRC and RSV did not affect ACh-induced vasodilation. For each set of experiments, $n = 4$ rats.

Physical interaction between PAR₂ and TLR4 in naïve and LPS-treated rats

To gain further insights into the molecular mechanism of PAR₂/TLR4 cross-talk an immunoprecipitation study was carried up. In homogenates of aortas obtained from both naïve and LPS-treated rats, immunoprecipitation of TLR4 receptor followed by PAR₂ immunoblot was performed. Immunoblotting of anti-TLR4 immunoprecipitates with anti-PAR₂ revealed that PAR₂ was associated with the TLR4 receptor, as a 40-kDa band consistent with PAR₂ core protein (Gruber *et al.*, 2004) was obtained (Figure 6B lane B). The complex between the PAR₂ and TLR4 receptor was also evident after *in vitro* stimulation of aortas with PAR₂AP (Figure 6B lane D). These results suggest that PAR₂ was associated with TLR4 before, as well as, after receptor activation. Similar findings have also been obtained in aortas obtained from endotoxaemic animals (Figure 6B lane E–H). To evaluate the specificity of the 40-kDa band, cell lysates of aortas stimulated or not with PAR₂AP from control and endotoxaemic rats were incubated with the corresponding normal rabbit serum instead of anti-TLR-4 antibody (Figure 6B lanes A, C, E, and G). Western blot analysis performed on the supernatants obtained from anti-TLR4 immunoprecipitates revealed the presence of PAR₂ receptors exclusively in aortas harvested from LPS-treated rats (Figure 6C).

PAR₂ expression is reduced in TLR4^{-/-} mice

In order to confirm the cooperation between PAR₂ and TLR4 receptors, we performed a functional study on TLR4^{-/-} mice. In isolated aortic rings from these mice both ACh-induced vasodilation and the endothelium-independent dilator agent SNP (sodium nitroprusside), induced a similar sized response in TLR4^{-/-} and wild-type mice (Figure 4A and B). RT-PCR analysis revealed a significant reduction in PAR₂ expression in aortas of TLR4^{-/-} mice compared with those from wild-type mice (Figure 7A). This finding was confirmed in the functional study where, PAR₂AP-induced vasorelaxation was significantly reduced in aortic rings harvested from TLR4^{-/-} mice compared with wild-type mice (Figure 7C). Western blot analysis for PAR₂ did not reveal any significant difference between TLR4^{-/-} and wild-type mice (Figure 7B).

Discussion

We have previously shown that PAR₂ is involved in LPS-induced hypotension; however, we did not elucidate the mechanism underlying this involvement of PAR₂ in septic shock (Cicala *et al.*, 1999). At the time, it was not known that the action of LPS mainly produced through an effect on the TLR4 receptor. Following recent evidence suggesting a possible connection between PARs and TLR signalling (Moretti *et al.*, 2008; Rallabhandi *et al.*, 2008; Uehara *et al.*, 2008), here we sought to investigate any possible cross-talk between the PAR₂ and TLR4 in vascular tissues. To pursue this, we used two different approaches: the first *ex vivo*, pharmacological modulation of isolated aortic rings obtained from naïve and endotoxaemic rats. The second *in vivo*, using PAR₂AP-induced hypotension in anaesthetized rats in order to validate the data obtained *ex vivo*. The rationale for using aorta from LPS-treated rats relies on the finding that LPS injection induces an increase in PAR₂ expression in vascular tissue.

Firstly, we evaluated whether RSV and CRC, two recently recognized TLR4 antagonists (Youn *et al.*, 2006; Son *et al.*, 2008; Lubbad *et al.*, 2009), could reduce PAR₂AP-induced vasorelaxation. In aortas from both control and LPS-treated rats, both of these antagonists significantly inhibited the PAR₂AP-induced vasodilation without affecting NO release. The specificity of these effects of CRC and RSV on TLR4 receptor were confirmed by using aortic rings from TLR4^{-/-} mice; the two antagonists had no effect on PAR₂AP-induced vasodilation in aortic rings obtained from TLR4^{-/-}, while both retained their inhibitory activity on aortas obtained from C57BL/10ScN mice. The finding that the TLR4 antagonists had similar effects in aortic rings from either control or LPS-treated rats suggests that a constitutive functional interaction may exist between PAR₂ and TLR4. This latter result together with the finding that PAR₂, but not TLR4, expression is increased in aortic tissue obtained from rats 4 and 8 h after they had been injected with LPS, indicate that the PAR₂ over-expressed following LPS treatment is not physically associated with TLR4. This LPS-induced increase in the expression of the PAR₂, measured by quantitative RT-PCR, was also observed in the aortas and kidneys harvested from TLR4^{-/-}




Figure 2

(A) PAR₂-AP-induced vasorelaxation was significantly and concentration-dependently inhibited by CRC in aortic rings harvested from control rats (*** $P < 0.001$ versus vehicle; two-way ANOVA). CRC (10 μ M) pretreatment also inhibited PAR₂-AP-induced vasorelaxation in aortic rings harvested from LPS-treated rats at (B) 4 h (*** $P < 0.001$ vs. vehicle) and (C) 8 h (*** $P < 0.001$ vs. vehicle; for each set of experiments, $n = 5$ rats).




Figure 3

(A) PAR₂-AP-induced vasorelaxation was significantly and concentration-dependently inhibited by RSV in aortic rings harvested from control rats (*** $P < 0.001$ vs. vehicle; two-way ANOVA). RSV (10 μ M) pretreatment also inhibited PAR₂-AP vasorelaxation in aortic rings harvested from LPS-treated rats at (B) 4 h (*** $P < 0.001$ vs. vehicle) and (C) 8 h (*** $P < 0.001$ vs. vehicle; for each set of experiments $n = 5$ rats).




Figure 4

ACh-induced vasodilation (10 nM–30 μM) (A), as well as SNP-induced vasodilation (1 nM–3 μM) (B), were not significantly different in isolated aortic rings harvested from TLR4^{-/-} mice compared with wild-type littermates, (C) incubation with CRC or RSV did not affect PAR₂AP-induced vasodilation in aortic rings harvested from TLR4^{-/-} mice. $n = 6$ for each group of animals.

mice (Supporting Information Figure S2) confirming that LPS-induced PAR₂ overexpression is independent of TLR4 expression not only in the vasculature but also in other tissues. Hence, the results of this immunoprecipitation study suggest that PAR₂ can interact with TLR4 in normal conditions and that LPS treatment does not increase this interaction. These data are in line with our hypothesis that the PAR₂/TLR4 association is constitutive in vascular tissue and LPS-induced PAR₂ overexpression does not involve a further increase in the interaction of PAR₂ with TLR4. However, as shown in Supporting Information Figure S3, the PAR₂ monoclonal antibody SAM11 appears to cross-react with an




Figure 5

PAR₂AP-induced hypotension (0.3 mg·kg⁻¹ i.v.) was significantly reduced in control rats treated either with (A) CRC or (B) RSV (* $P < 0.05$; one way ANOVA, $n = 4$ for each treatment). Values were expressed as area under the curve (mm²).

unknown target in proteins isolated from PAR₂ knockout mice, as also shown by others (Kagota *et al.*, 2011). In addition, the same applies to the polyclonal TLR4 antibody [TLR4 (M300) sc-30002] used in this study. Therefore the antibody reagents available are not yet reliable enough to clearly establish this interaction in intact tissues.

In order to test whether the above findings are also relevant *in vivo*, we treated naïve rats with RSV or CRC and then induced hypotension by a bolus injection of PAR₂AP. CRC and RSV significantly reduced PAR₂AP-induced hypotension; the dose of these antagonist used is known to specifically inhibit TLR4, as opposed to higher doses (Bengmark, 2006; Silan, 2008). These data suggest that TLR4 signalling is involved in PAR₂ activation. The fact that RSV, the MyD88-independent TRIF-dependent pathway inhibitor, was a more potent inhibitor than CRC in both the *ex vivo* and *in vivo* experiments suggests that PAR₂ activation might involve this specific TLR4 signalling pathway. This mechanism has previously been proposed by Rallabhandi and colleagues, from results obtained using transiently PAR₂ transfected HEK293T cells (Rallabhandi *et al.*, 2008). Thus, our data obtained *in vivo* confirm the results obtained from our *ex vivo* experiments, all indicating that PAR₂/TLR4 cross-talk is involved in the modulation of the vascular tone in physiological conditions. When a pathological stimulus occurs, such as LPS injection, there is an overexpression of PAR₂ that is no longer associated with TLR4.

The experiments carried out in TLR4^{-/-} mice provide a proof of concept of this cross-talk between PAR₂ and TLR4. RT-PCR analysis showed that the aortas obtained from TLR4^{-/-} mice had a reduced expression of PAR₂. Similarly, the functional study revealed a significant reduction in PAR₂AP-induced vasodilation in aortic rings from TLR4^{-/-} mice




Figure 6

(A) Physical association of PAR₂ with TLR4. Anti PAR₂ immunoblot of antiTLR4 (lanes B, D, F and H) and normal rabbit serum control (lanes A, C, E and G) immunoprecipitation from lysates of aortas incubated in the absence (lanes A, B, E and F) and presence of PAR₂AP (lanes C, D, G and H) in naïve (lanes A, B, C, D) and endotoxaemic (lanes E, F, G, H) rats ($n = 3$ experiments). (B) Western blot analysis for PAR₂ receptor performed on supernatants of TLR4 immunoprecipitates showed the presence of PAR₂ exclusively in aortas harvested from LPS-treated rats ($n = 3$ experiments).

compared to wild-type mice. In order to assess the vascular reactivity of TLR4^{-/-} mice, we checked both endothelium-dependent (with ACh) and endothelium-independent (with SNP) vasodilatation and showed that this was not significantly different from that of wild-type mice. These data indicate that, in the absence of TLR4, PAR₂ signalling is impaired most likely because of the lack of cooperation between PAR₂ and TLR4.

Conclusions

Our study demonstrates that in vascular tissues, PAR₂ and TLR4 cooperate in terms of molecular signalling both in physiological and pathological conditions. LPS priming causes an overexpression of PAR₂, which exceeds the TLR4 binding capacity. This finding sheds new light on the dual role of PAR₂ in physiological versus pathological conditions.




Figure 7

(A) RT-PCR analysis performed on aortas harvested from TLR4^{-/-} and wild-type mice showed a reduction of PAR₂ expression in TLR4^{-/-} mice (* $P < 0.05$, $n = 3$ experiments). (B) Western blot analysis of PAR₂ performed on lysates of aortas harvested from TLR4^{-/-} and wild-type mice revealed no significant differences between the strains ($n = 3$ experiments). (C) PAR₂AP-induced vasorelaxation was significantly impaired in aortic rings harvested from TLR4^{-/-} mice (** $P < 0.001$, $n = 7$ for each strain).

Indeed, we hypothesize that when the amount of PAR₂ expressed exceeds TLR4 binding capacity, PAR₂ could elicit a detrimental effect. Conversely, when all the PAR₂ expressed are bound to TLR4 it would have a beneficial physiological effect. Our findings could explain why in some cases activa-

tion of PAR₂ has been found to induce anti-inflammatory effects (Fiorucci *et al.*, 2001; Morello *et al.*, 2005; Roviezzo *et al.*, 2005), whereas others have demonstrated that it results in pro-inflammatory effects (Fiorucci *et al.*, 2001; Ferrell *et al.*, 2003; Hyun *et al.*, 2008), and they also help to unravel the complex role played by this protease-activated receptor in cardiovascular homeostasis.

Acknowledgements

We would like to thank Prof. Carla Cicala for her precious suggestions and support. This work was supported by Ministero della Università e della Ricerca (MIUR) PRIN 2008 Italy.

Conflict of interest

None declared.

References

- Aderem A, Ulevitch R (2000). Toll-like receptors in the induction of the innate immune response. *Nature* 406: 782–787.
- Akira S, Hemmi H (2003). Recognition of pathogen-associated molecular patterns by TLR family. *Immunol Lett* 85: 85–95.
- Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. *Cell* 124: 783–801.
- Barton GM, Medzhitov R (2004). Toll signalling: RIPPING off the TNF pathway. *Nat Immunol* 5: 472–474.
- Bengmark S (2006). Curcumin, an atoxic antioxidant and natural NFκB, cyclooxygenase-2, lipoxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. *JPEN J Parenter Enteral Nutr* 30: 45–51.
- Bucci M, Roviezzo F, Cirino G (2005). Protease-activated receptor-2 (PAR2) in cardiovascular system. *Vascul Pharmacol* 43: 247–253.
- Chung WO, An JY, Yin L, Hacker BM, Rohani MG, Dommisch H *et al.* (2010). Interplay of protease-activated receptors and NOD pattern recognition receptors in epithelial innate immune responses to bacteria. *Immunol Lett* 131: 113–119.
- Cicala C (2002). Protease activated receptor 2 and the cardiovascular system. *Br J Pharmacol* 135: 14–20.
- Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P *et al.* (1999). Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. *Circulation* 99: 2590–2597.
- Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G (2001). Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. *FASEB J* 15: 1433–1435.
- Cottrell GS, Amadesi S, Schmidlin F, Bunnett N (2003). Protease-activated receptor 2: activation, signalling and function. *Biochem Soc Trans* 31: 1191–1197.
- Dery O, Corvera CU, Steinhoff M, Bunnett NW (1998). Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. *Am J Physiol* 274: C1429–C1452.
- Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE *et al.* (2003). Essential role for proteinase-activated receptor-2 in arthritis. *J Clin Invest* 11: 35–41.
- Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD *et al.* (2001). Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. *Proc Natl Acad Sci U S A* 98: 13936–13941.
- Fox MT, Harriot P, Walker B, Stone SR (1997). Identification of potential activators of proteinase activated receptor 2. *FEBS Lett* 417: 267–269.
- Gruber BL, Marchese MJ, Santiago-Schwarz F, Martin CA, Zhang J, Kew RR (2004). Protease-activated receptor-2 (PAR-2) expression in human fibroblasts is regulated by growth factors and extracellular matrix. *J Invest Dermatol* 123: 832–839.
- Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, Baruch A *et al.* (2005). A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. *Proc Natl Acad Sci U S A* 102: 8363–8368.
- Hoffmann JA, Reichhart JM (2002). Drosophila innate immunity: an evolutionary perspective. *Nat Immunol* 3: 121–126.
- Hollenberg MD (1999). Protease-activated receptors: PAR4 and counting: how long is the course? *Trends Pharmacol Sci* 20: 271–273.
- Hollenberg MD, Compton SJ (2002). International Union of Pharmacology XXVIII Proteinase-activated receptors. *Pharmacol Rev* 54: 203–217.
- Holzhausen M, Spolidorio LC, Ellen RP, Jobin MC, Steinhoff M, Andrade-Gordon P *et al.* (2006). Protease-activated receptor-2 activation: a major role in the pathogenesis of *Porphyromonas gingivalis* infection. *Am J Pathol* 168: 1189–1199.
- Hyun E, Andrade-Gordon P, Steinhoff M, Vergnolle N (2008). Protease-activated receptor-2 activation: a major actor in intestinal inflammation. *Gut* 57: 1222–1229.
- Iwasaki A, Medzhitov R (2004). Toll-like receptor control of the adaptive immune responses. *Nat Immunol* 5: 987–995.
- Janeway CA Jr, Medzhitov R (2002). Innate immune recognition. *Annu Rev Immunol* 20: 197–216.
- Kagota S, Chia E, McGuire JJ (2011). Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice. *Br J Pharmacol* 164: 358–371.
- Kida Y, Inoue H, Shimizu T, Kuwano K (2007). *Serratia marcescens* serralyisin induces inflammatory responses through protease-activated receptor 2. *Infect Immun* 75: 164–174.
- Kida Y, Higashimoto Y, Inoue H, Shimizu T, Kuwano K (2008). A novel secreted protease from *Pseudomonas aeruginosa* activates NF-κB through protease-activated receptors. *Cell Microbiol* 10: 1491–1504.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. *Br J Pharmacol* 160: 1577–1579.
- Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402–408.
- Lolis E, Bucala R (2003). Therapeutic approaches to innate immunity: severe sepsis and septic shock. *Nat Rev Drug Discov* 2: 635–645.

- Lubbad A, Oriowo MA, Khan I (2009). Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. *Mol Cell Biochem* 322: 127–135.
- Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001). Proteinase activated receptors. *Pharmacol Rev* 53: 245–282.
- McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. *Br J Pharmacol* 160: 1573–1576.
- Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster S, Cartwright N (2007). Critical role of Toll-like receptors and nucleotide oligomerization domain in the regulation of health and disease. *J Endocrinol* 53: 245–282.
- Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A *et al.* (1997). Interactions of mast cell tryptase with thrombin receptors and PAR-2. *J Biol Chem* 272: 4043–4049.
- Morello S, Vellecco V, Roviezzo F, Maffia P, Cuzzocrea S, Cirino G *et al.* (2005). A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats. *Biochem Pharmacol* 71: 223–230.
- Moretti S, Bellocchio S, Bonifazi P, Bozza S, Zelante T, Bistoni F *et al.* (2008). The contribution of PARs to inflammation and immunity to fungi. *Mucosal Immunol* 1: 156–168.
- Nakamura N, Yoshida M, Umeda M, Huang Y, Kitajima S, Inoue Y *et al.* (2008). Extended exposure of lipopolysaccharide fraction from *Porphyromonas gingivalis* facilitates mononuclear cell adhesion to vascular endothelium via toll-like receptor-2 dependent mechanism. *Atherosclerosis* 196: 59–67.
- Nystedt S, Emilsson K, Wahlestedt C, Sundelin J (1994). Molecular cloning of a potential proteinase activated receptor. *Proc Natl Acad Sci U S A* 91: 9208–9212.
- Nystedt S, Ramakrishnan V, Sundelin J (1996). The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. *J Biol Chem* 271: 14910–14915.
- O'Neill LA, Bowie AG (2007). The family of five: TIR-domain-containing adaptors in toll-like receptor signalling. *Nat Rev Immunol* 7: 353–364.
- Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X *et al.* (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282: 2085–2088.
- Poltorak A, Smirnova I, Clisch R, Beutler B (2000). Limits of a deletion spanning Tlr4 in C57BL/10ScCr mice. *J Endotoxin Res* 6: 51–56.
- Rallabhandi P, Nhu QM, Toshchakov VY, Piao W, Medvedev AE, Hollenberg MD *et al.* (2008). Analysis of proteinase-activated receptor 2 and TLR4 signal transduction. *J Biol Chem* 283: 24314–24325.
- Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD *et al.* (2005). The evolution of vertebrate Toll-like receptors. *Proc Natl Acad Sci U S A* 102: 9577–9582.
- Roviezzo F, Bucci M, Brancaleone V, Di Lorenzo A, Geppetti P, Farneti S *et al.* (2005). Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. *Arterioscler Thromb Vasc Biol* 25: 2349–2354.
- Silan C (2008). The effect of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. *Biol Pharm Bull* 31: 897–902.
- Son YH, Jeong YT, Lee KA, Choi KH, Kim SM, Rhim BY *et al.* (2008). Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. *J Cardiovasc Pharmacol* 51: 71–77.
- Uehara A, Hirabayashi Y, Takada H (2008). Antibodies to proteinase 3 prime human oral, lung, and kidney epithelial cells to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1, and NOD2. *Clin Vaccine Immunol* 15: 1060–1066.
- Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH (2005). Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. *J Immunol* 175: 3339–3346.
- Youn HS, Saitoh SI, Miyake K, Hwang DH (2006). Inhibition of homodimerization of Toll-like receptor 4 by curcumin. *Biochem Pharmacol* 72: 62–69.
- Zhang Z, Schluesener HJ (2006). Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. *Cell Mol Life Sci* 63: 2901–2907.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1 (A) Western blot analysis shows a significant increase in PAR₂ expression in LPS (13.6 U·kg⁻¹) treated rats. (B) PAR₂AP-induced vasodilatation was significantly increased in aortic rings harvested from LPS-treated rats (4 and 8 h after LPS) **P* < 0.05 versus saline; ****P* < 0.001 versus saline; *n* = 10 for each group. (C) Western blot analysis revealed no difference in TLR4 expression in LPS-treated compared with naive rats.

Figure S2 qRT-PCR analysis performed on kidney (A) or on aorta (B) harvested from TLR4^{-/-} mice demonstrates that LPS causes an upregulation of PAR₂ expression. (**P* < 0.05 ****P* < 0.001; *n* = 3 experiments).

Figure S3 (A) Western blot analysis showing PAR₂ expression in aorta from wild-type and PAR₂ KO mice. (B) Western blot analysis showing TLR4 expression in aorta from wild-type and TLR4 KO mice. Blots are representative of 3 different experiments. (C) CRC (10 μM) and RSV (10 μM) significantly inhibited PAR₂AP-induced vasodilatation in aorta harvested from C57BL/10ScN mice (*** = *P* < 0.001 vs. vehicle; *n* = 3 mice for a total of 10 rings for each group).